Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2020-03-11 Capital/Financing Update
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
FORM S-1 AMENDMENT NO. 9
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A (Amendment No. 9) registration statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for a securities offering by BioVie Inc. The text includes detailed information about the securities being registered, offering terms, use of proceeds, risk factors, management discussion, and other disclosures typical of a registration statement for an initial or follow-on public offering. This is not a financial report, earnings release, or management discussion report, but a capital raising filing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not just an announcement or notice, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2020-03-11 English
RW
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting the withdrawal of a previously filed Registration Statement on Form 8-A/A. It is a regulatory communication about a filing withdrawal and does not contain financial data, report content, or detailed disclosures. The document is short (987 characters) and serves as a formal notice to the regulator rather than a financial report or announcement to shareholders. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2020-02-14 English
FORM 10-Q FOR PERIOD ENDING DECEMBER 31, 2019
Interim / Quarterly Report Q2 2020
2020-02-13 English
FORM S-1 AMENDMENT NO. 8
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A (Amendment No. 8) filed with the U.S. Securities and Exchange Commission, which is a registration statement under the Securities Act of 1933. It is used by companies to register securities for public offering, including detailed information about the offering, company business, management, financials, and risk factors. The text includes a preliminary prospectus for a public offering of units consisting of common stock and warrants, with details on underwriting, risk factors, and business description. This type of filing is related to capital raising activities and is not an annual report, earnings release, or other financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-11-23 English
FORM 10-Q FOR PERIOD ENDING SEPT 30, 2019
Interim / Quarterly Report Q1 2020
2019-11-19 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a patent challenge decision by the Patent Trial and Appeal Board affecting the company's patent, details about potential appeals, and clarifications about orphan drug designations and pending patent applications. There are no financial statements or detailed financial performance data. The document is not an annual or quarterly report, earnings release, or management discussion. It is an event disclosure about a legal/regulatory matter related to patents. Given the nature of the content and the form type (8-K), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it is itself the report of the event. Therefore, classification as RNS is appropriate with high confidence.
2019-11-15 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.